Episode Description
Aditya Kotta, Head of Business Development, US and Europe at Novotech, explores the evolving landscape of early phase oncology clinical trials. Drawing on over 15 years in the CRO industry, Aditya offers a grounded, data-informed perspective on how biotech companies can navigate increasingly complex trial demands.
Listeners will gain actionable insights into:
- Emerging trends in early phase oncology, particularly for Phase I and II programs.
- Key considerations in study design, site selection, and patient recruitment.
- The growing importance of scenario planning, including regulatory, cost-benefit, and geographic analysis.
- The shift toward global hybrid trial strategies that incorporate regions like Australia, APAC, Eastern Europe, and the US.
- Competitive dynamics with China-based clinical programs and how early-stage biotechs can evaluate their positioning.
Aditya also presents a real-world case study of a biotech company managing regulatory hurdles and dosing strategy decisions—illustrating how Novotech helps clients adapt with flexible trial models and cross-regional expertise.
Whether you're leading clinical operations or evaluating your early phase strategy, this episode delivers practical guidance for accelerating development timelines without compromising regulatory or scientific integrity.